INNT
TOTAL INVALIDATION PROCESSED BY THE IB
09/12/2025
Back to search
Official data from USPTO
RELZEPTIS METHOTREXATE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
09/13/2025
Trademark type
Combined
Nice classes
5
Filing date
11/30/2016
Registration date
02/20/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/06/2024
Last transaction
09/13/2025
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
5
Owner type
33
Owner location
FR
Examiner
JOHNSON, DANYTHE
Law office
N20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized word "RELZEPTIS" in which "REL" and "TIS" appears in black font and "ZEP" appears in grey font above the stylized green word "METHOTREXATE" with a green circle with a blue circle with a light mark at the top of the circle inside it to the upper right of the word "RELZEPTIS". The mark appears on a white background which is not claimed as a feature of the mark.
Holders and representatives
Holders
CROSSJECT
Representatives
Brooks R. Bruneau FisherBroyles, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products containing methotrexatepharmaceutical preparations for the treatment of polyarthritis and autoimmune diseases
Publications
History of USPTO decisions and trademark events.
39 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
08/28/2025
INPC
INVALIDATION PROCESSED
08/28/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
05/06/2025
C71T
CANCELLED SECTION 71
09/06/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/20/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/14/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/25/2018
FIMP
FINAL DISPOSITION PROCESSED
05/25/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/20/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
02/20/2018
GPNX
NOTIFICATION PROCESSED BY IB
12/09/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/05/2017
PUBO
PUBLISHED FOR OPPOSITION
12/05/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/22/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/22/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/15/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/21/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
10/20/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/20/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
10/20/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/20/2017
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
10/20/2017
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
10/17/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/03/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/02/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/12/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/12/2017
ALIE
ASSIGNED TO LIE
09/10/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/29/2017
RFNT
REFUSAL PROCESSED BY IB
06/24/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/03/2017
RFRR
REFUSAL PROCESSED BY MPU
06/03/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/21/2017
CNRT
NON-FINAL ACTION WRITTEN
05/20/2017
MAFR
APPLICATION FILING RECEIPT MAILED
05/17/2017
DOCK
ASSIGNED TO EXAMINER
05/13/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/13/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/11/2017
Continuous trademark protection
Get notified about every new filing that threatens RELZEPTIS METHOTREXATE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.